Table 4 AR therapeutic management by the interviewed physicians
Item | Whole sample | Allergologists | ENTs | GPs | p-value |
|---|---|---|---|---|---|
N = 2823 | N = 909 | N = 606 | N = 1308 | ||
Main prescription drivers | < 0.001 | ||||
Effective on all AR symptoms | 1533 (54.3%) | 501 (55.1%) | 335 (55.2%) | 697 (53.2%) | |
Quick symptom relief | 1352 (47.8%) | 429 (47.1%) | 287 (47.3%) | 636 (48.6%) | |
Increased patient adherence | 959 (33.9%) | 255 (28%) | 242 (39.9%) | 462 (35.3%) | |
Sustained efficacy | 921 (32.6%) | 307 (33.7%) | 189 (31.1%) | 425 (32.4%) | |
Few/no side effects | 911 (32.2%) | 303 (33.3%) | 164 (27%) | 444 (33.9%) | |
Effective with few drugs | 849 (30%) | 290 (31.9%) | 198 (32.6%) | 361 (27.5%) | |
Easy to take | 848 (30%) | 228 (25%) | 192 (31.6%) | 428 (32.7%) | |
Supported by scientific literature | 470 (16.6%) | 216 (23.7%) | 127 (20.9%) | 127 (9.7%) | |
Affordable price | 379 (13.4%) | 137 (15%) | 70 (11.5%) | 172 (13.1%) | |
Refundable | 246 (8.7%) | 60 (6.6%) | 14 (2.3%) | 172 (13.1%) | |
Follow-up timing | < 0.001 | ||||
< 12 months | 86 (3%) | 36 (4%) | 24 (4%) | 26 (2%) | |
Every 12 months | 1166 (41%) | 427 (47%) | 242 (40%) | 497 (38%) | |
Every 6 months | 722 (26%) | 272 (30%) | 188 (31%) | 262 (20%) | |
< 6 months | 865 (31%) | 172 (19%) | 157 (26%) | 536 (41%) | |
Treatment regimen | < 0.001 | ||||
Monotherapy | 1170 (41.4%) | 303 (33.3%) | 246 (40.5%) | 621 (47.4%) | |
Polytherapy | 1653 (59.6%) | 606 (66.7%) | 360 (59.4%) | 687 (52.5%) | |